CAR-T cells expressing monomeric APRIL had limited clinical efficacy, but those expressing trimeric APRIL not only were able to eliminate BCMA+ MM, but also able to eliminate BCMA- MM in the animal models [36]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.